Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2C8 CYP2C9 CYP2C18 CYP2D6	9.14e-06	27	99	4	GO:0008391
GeneOntologyMolecularFunction	histone H2BS36 kinase activity	PRKAA1 PRKAA2	2.43e-05	2	99	2	GO:0140823
GeneOntologyMolecularFunction	[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity	PRKAA1 PRKAA2	2.43e-05	2	99	2	GO:0047322
GeneOntologyMolecularFunction	histone H2B kinase activity	PRKAA1 PRKAA2	2.43e-05	2	99	2	GO:0140998
GeneOntologyMolecularFunction	aromatase activity	CYP2C8 CYP2C9 CYP2C18 CYP2D6	2.65e-05	35	99	4	GO:0070330
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C8 CYP2C9 CYP2C18	4.14e-05	14	99	3	GO:0008401
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.01e-04	49	99	4	GO:0016712
GeneOntologyMolecularFunction	heme binding	CYP2C8 CYP2C9 CYP2C18 CYP2D6 EPX NOS2	1.18e-04	154	99	6	GO:0020037
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C9 CYP2C18	1.45e-04	4	99	2	GO:0071614
GeneOntologyMolecularFunction	tetrapyrrole binding	CYP2C8 CYP2C9 CYP2C18 CYP2D6 EPX NOS2	1.67e-04	164	99	6	GO:0046906
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2C8 CYP2C9 CYP2C18	2.22e-04	24	99	3	GO:0008392
GeneOntologyMolecularFunction	monooxygenase activity	CYP2C8 CYP2C9 CYP2C18 CYP2D6 NOS2	2.70e-04	115	99	5	GO:0004497
GeneOntologyMolecularFunction	steroid hydroxylase activity	CYP2C8 CYP2C9 CYP2D6	6.33e-04	34	99	3	GO:0008395
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C8 CYP2C9	6.68e-04	8	99	2	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C8 CYP2C9	6.68e-04	8	99	2	GO:0034875
GeneOntologyMolecularFunction	AMP-activated protein kinase activity	PRKAA1 PRKAA2	1.07e-03	10	99	2	GO:0004679
GeneOntologyMolecularFunction	ligase activity, forming carbon-oxygen bonds	AARS1 LARS1 FARS2	1.18e-03	42	99	3	GO:0016875
GeneOntologyMolecularFunction	aminoacyl-tRNA ligase activity	AARS1 LARS1 FARS2	1.18e-03	42	99	3	GO:0004812
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP2C8 CYP2C9	1.30e-03	11	99	2	GO:0101020
GeneOntologyMolecularFunction	protein serine/threonine kinase activity	ERN1 SPEG CDK11A ACVR2A MTOR PRKAA1 PRKAA2 DMPK	1.69e-03	446	99	8	GO:0004674
GeneOntologyMolecularFunction	aminoacyl-tRNA editing activity	AARS1 LARS1	2.13e-03	14	99	2	GO:0002161
GeneOntologyMolecularFunction	protein serine kinase activity	ERN1 SPEG CDK11A MTOR PRKAA1 PRKAA2 DMPK	2.20e-03	363	99	7	GO:0106310
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C8 CYP2C9	2.45e-03	15	99	2	GO:0016725
GeneOntologyMolecularFunction	Hsp90 protein binding	ERN1 SLC12A2 NOS2	2.57e-03	55	99	3	GO:0051879
GeneOntologyMolecularFunction	phosphotransferase activity, alcohol group as acceptor	ERN1 SPEG SCYL3 CDK11A DGKZ ACVR2A MTOR PRKAA1 PRKAA2 DMPK	2.71e-03	709	99	10	GO:0016773
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	CYP2C8 CYP2C9 CYP2C18 CYP2D6 NOS2	2.81e-03	194	99	5	GO:0016705
GeneOntologyMolecularFunction	protein kinase activity	ERN1 SPEG SCYL3 CDK11A ACVR2A MTOR PRKAA1 PRKAA2 DMPK	2.95e-03	600	99	9	GO:0004672
GeneOntologyMolecularFunction	beta-catenin binding	CDHR5 CDH4 NOS2 CDH18	3.01e-03	120	99	4	GO:0008013
GeneOntologyBiologicalProcess	positive regulation of peptidyl-lysine acetylation	DIP2A PRKAA1 PRKAA2	3.82e-06	7	100	3	GO:2000758
GeneOntologyBiologicalProcess	long-chain fatty acid biosynthetic process	CYP2C8 CYP2C9 CYP2D6 QKI	1.13e-05	29	100	4	GO:0042759
GeneOntologyBiologicalProcess	positive regulation of granulosa cell proliferation	MTA3 MTOR	2.33e-05	2	100	2	GO:1904197
GeneOntologyBiologicalProcess	regulation of granulosa cell proliferation	MTA3 MTOR	2.33e-05	2	100	2	GO:1904195
GeneOntologyBiologicalProcess	granulosa cell proliferation	MTA3 MTOR	2.33e-05	2	100	2	GO:1990739
GeneOntologyBiologicalProcess	oxidative demethylation	CYP2C8 CYP2C9 CYP2D6	2.36e-05	12	100	3	GO:0070989
GeneOntologyBiologicalProcess	regulation of peptidyl-lysine acetylation	DIP2A PRKAA1 PRKAA2	2.36e-05	12	100	3	GO:2000756
GeneOntologyBiologicalProcess	positive regulation of protein acetylation	DIP2A PRKAA1 PRKAA2	8.56e-05	18	100	3	GO:1901985
GeneOntologyBiologicalProcess	cellular response to xenobiotic stimulus	CYP2C8 CYP2C9 CYP2C18 CYP2D6 PRKAA1 PRKAA2 NOS2	1.04e-04	222	100	7	GO:0071466
GeneOntologyBiologicalProcess	protein localization to lipid droplet	PRKAA1 PRKAA2	1.39e-04	4	100	2	GO:1990044
GeneOntologyBiologicalProcess	positive regulation of nucleotide metabolic process	MTOR PRKAA1 PRKAA2 NOS2	1.47e-04	55	100	4	GO:0045981
GeneOntologyBiologicalProcess	positive regulation of purine nucleotide metabolic process	MTOR PRKAA1 PRKAA2 NOS2	1.47e-04	55	100	4	GO:1900544
GeneOntologyBiologicalProcess	epoxygenase P450 pathway	CYP2C8 CYP2C9 CYP2C18	1.59e-04	22	100	3	GO:0019373
GeneOntologyBiologicalProcess	demethylation	CYP2C8 CYP2C9 CYP2D6	2.08e-04	24	100	3	GO:0070988
GeneOntologyBiologicalProcess	T-helper 1 cell lineage commitment	TBX21 MTOR	2.31e-04	5	100	2	GO:0002296
GeneOntologyBiologicalProcess	monocarboxylic acid biosynthetic process	CYP2C8 CYP2C9 CYP2D6 OSBPL2 PRKAA1 PRKAA2 QKI	2.76e-04	260	100	7	GO:0072330
GeneOntologyBiologicalProcess	regulation of protein acetylation	DIP2A PRKAA1 PRKAA2	3.32e-04	28	100	3	GO:1901983
GeneOntologyBiologicalProcess	peptidyl-lysine acetylation	DIP2A PRKAA1 PRKAA2	3.32e-04	28	100	3	GO:0018394
GeneOntologyBiologicalProcess	arachidonate metabolic process	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.34e-04	68	100	4	GO:0019369
GeneOntologyBiologicalProcess	fatty acid biosynthetic process	CYP2C8 CYP2C9 CYP2D6 PRKAA1 PRKAA2 QKI	3.38e-04	191	100	6	GO:0006633
GeneOntologyBiologicalProcess	monoterpenoid metabolic process	CYP2C9 CYP2D6	3.45e-04	6	100	2	GO:0016098
GeneOntologyBiologicalProcess	long-chain fatty acid metabolic process	CYP2C8 CYP2C9 CYP2C18 CYP2D6 QKI	3.46e-04	124	100	5	GO:0001676
GeneOntologyBiologicalProcess	positive regulation of glycolytic process	MTOR PRKAA1 PRKAA2	3.69e-04	29	100	3	GO:0045821
GeneOntologyBiologicalProcess	positive regulation of nucleotide catabolic process	MTOR PRKAA1 PRKAA2	3.69e-04	29	100	3	GO:0030813
GeneOntologyBiologicalProcess	positive regulation of purine nucleotide catabolic process	MTOR PRKAA1 PRKAA2	3.69e-04	29	100	3	GO:0033123
GeneOntologyBiologicalProcess	plasma membrane bounded cell projection assembly	WHAMM TENM2 PLEKHM1 SEPTIN6 WDR19 CEP350 CELSR3 MTOR ADAMTS16 AUTS2 WDR90	4.03e-04	670	100	11	GO:0120031
GeneOntologyBiologicalProcess	lipid droplet disassembly	PRKAA1 PRKAA2	4.81e-04	7	100	2	GO:1905691
GeneOntologyBiologicalProcess	negative regulation of tubulin deacetylation	PRKAA1 PRKAA2	4.81e-04	7	100	2	GO:1904428
GeneOntologyBiologicalProcess	cell projection assembly	WHAMM TENM2 PLEKHM1 SEPTIN6 WDR19 CEP350 CELSR3 MTOR ADAMTS16 AUTS2 WDR90	4.85e-04	685	100	11	GO:0030031
MousePheno	increased Ly6C low monocyte number	ARHGEF1 HERC1 TRAPPC9	1.37e-05	8	89	3	MP:0013025
Domain	AMPK_C	PRKAA1 PRKAA2	2.84e-05	2	100	2	IPR032270
Domain	AdenylateSensor	PRKAA1 PRKAA2	2.84e-05	2	100	2	PF16579
Domain	Cyt_P450_E_grp-I	CYP2C8 CYP2C9 CYP2C18 CYP2D6	9.74e-05	45	100	4	IPR002401
Domain	Cyt_P450_CS	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.85e-04	53	100	4	IPR017972
Domain	CYTOCHROME_P450	CYP2C8 CYP2C9 CYP2C18 CYP2D6	2.46e-04	57	100	4	PS00086
Domain	-	CYP2C8 CYP2C9 CYP2C18 CYP2D6	2.63e-04	58	100	4	1.10.630.10
Domain	p450	CYP2C8 CYP2C9 CYP2C18 CYP2D6	2.63e-04	58	100	4	PF00067
Domain	DMAP_binding	DIP2A DIP2C	2.81e-04	5	100	2	PF06464
Domain	Cyt_P450	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.00e-04	60	100	4	IPR001128
Domain	CADHERIN_1	CDHR5 CLSTN2 CELSR3 CDH4 CDH18	3.54e-04	113	100	5	PS00232
Domain	CADHERIN_2	CDHR5 CLSTN2 CELSR3 CDH4 CDH18	3.68e-04	114	100	5	PS50268
Domain	-	CDHR5 CLSTN2 CELSR3 CDH4 CDH18	3.68e-04	114	100	5	2.60.40.60
Domain	CA	CDHR5 CLSTN2 CELSR3 CDH4 CDH18	3.83e-04	115	100	5	SM00112
Domain	Cadherin-like	CDHR5 CLSTN2 CELSR3 CDH4 CDH18	3.99e-04	116	100	5	IPR015919
Domain	DMAP1-bd	DIP2A DIP2C	4.20e-04	6	100	2	IPR010506
Domain	DMAP_binding	DIP2A DIP2C	4.20e-04	6	100	2	SM01137
Domain	Cadherin	CDHR5 CLSTN2 CELSR3 CDH4 CDH18	4.31e-04	118	100	5	IPR002126
Domain	KA1/Ssp2_C	PRKAA1 PRKAA2	5.86e-04	7	100	2	IPR028375
Domain	Kinase-like_dom	ERN1 SPEG SCYL3 CDK11A ACVR2A PTPN13 MTOR PRKAA1 PRKAA2 DMPK	6.51e-04	542	100	10	IPR011009
Domain	S_TKc	ERN1 SPEG SCYL3 CDK11A ACVR2A PRKAA1 PRKAA2 DMPK	6.90e-04	359	100	8	SM00220
Domain	Pkinase	ERN1 SPEG SCYL3 CDK11A ACVR2A PRKAA1 PRKAA2 DMPK	1.01e-03	381	100	8	PF00069
Domain	BAH	MTA3 BAHCC1	1.51e-03	11	100	2	SM00439
Domain	BAH	MTA3 BAHCC1	1.51e-03	11	100	2	PF01426
Domain	BAH	MTA3 BAHCC1	1.51e-03	11	100	2	PS51038
Domain	BAH_dom	MTA3 BAHCC1	1.51e-03	11	100	2	IPR001025
Domain	FAD-dep_OxRdtase	FOXRED1 SARDH	1.81e-03	12	100	2	IPR006076
Domain	DAO	FOXRED1 SARDH	1.81e-03	12	100	2	PF01266
Domain	WD40	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	2.70e-03	259	100	6	PF00400
Domain	Cadherin_CS	CDHR5 CELSR3 CDH4 CDH18	2.80e-03	109	100	4	IPR020894
Domain	Ser/Thr_kinase_AS	ERN1 SPEG CDK11A ACVR2A PRKAA1 PRKAA2 DMPK	3.08e-03	357	100	7	IPR008271
Domain	Cadherin	CLSTN2 CELSR3 CDH4 CDH18	3.19e-03	113	100	4	PF00028
Domain	WD40	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	3.19e-03	268	100	6	SM00320
Domain	PROTEIN_KINASE_ST	ERN1 SPEG CDK11A ACVR2A PRKAA1 PRKAA2 DMPK	3.32e-03	362	100	7	PS00108
Domain	WD40_repeat	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	3.44e-03	272	100	6	IPR001680
Domain	WD_REPEATS_1	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	3.82e-03	278	100	6	PS00678
Domain	WD_REPEATS_2	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	3.89e-03	279	100	6	PS50082
Domain	WD_REPEATS_REGION	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	3.89e-03	279	100	6	PS50294
Domain	DH_1	ARHGEF28 RASGRF1 ARHGEF1	4.69e-03	63	100	3	PS00741
Domain	Prot_kinase_dom	ERN1 SPEG SCYL3 CDK11A ACVR2A PRKAA1 PRKAA2 DMPK	4.74e-03	489	100	8	IPR000719
Domain	ZF_DAG_PE_1	ARHGEF28 DGKZ PLEKHM1	4.90e-03	64	100	3	PS00479
Domain	ZF_DAG_PE_2	ARHGEF28 DGKZ PLEKHM1	4.90e-03	64	100	3	PS50081
Domain	PROTEIN_KINASE_DOM	ERN1 SPEG SCYL3 CDK11A ACVR2A PRKAA1 PRKAA2 DMPK	4.97e-03	493	100	8	PS50011
Domain	Synaptotagmin	PCLO SYT9	5.06e-03	20	100	2	IPR001565
Domain	RCC1	RCC1L HERC1	5.06e-03	20	100	2	PF00415
Domain	C1	ARHGEF28 DGKZ PLEKHM1	5.12e-03	65	100	3	SM00109
Domain	WD40_repeat_dom	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	5.26e-03	297	100	6	IPR017986
Domain	PE/DAG-bd	ARHGEF28 DGKZ PLEKHM1	5.34e-03	66	100	3	IPR002219
Domain	RCC1_1	RCC1L HERC1	5.58e-03	21	100	2	PS00625
Domain	RCC1_2	RCC1L HERC1	5.58e-03	21	100	2	PS00626
Domain	RCC1_3	RCC1L HERC1	5.58e-03	21	100	2	PS50012
Domain	RhoGEF	ARHGEF28 RASGRF1 ARHGEF1	5.80e-03	68	100	3	SM00325
Domain	Reg_chr_condens	RCC1L HERC1	6.11e-03	22	100	2	IPR000408
Domain	-	RCC1L HERC1	6.11e-03	22	100	2	2.130.10.30
Domain	RhoGEF	ARHGEF28 RASGRF1 ARHGEF1	6.29e-03	70	100	3	PF00621
Pathway	REACTOME_BIOSYNTHESIS_OF_MARESIN_LIKE_SPMS	CYP2C8 CYP2C9 CYP2D6	2.75e-06	6	74	3	M27909
Pathway	REACTOME_XENOBIOTICS	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.74e-06	23	74	4	M5372
Pathway	REACTOME_BIOSYNTHESIS_OF_MARESINS	CYP2C8 CYP2C9 CYP2D6	7.63e-06	8	74	3	M27891
Pathway	REACTOME_CYP2E1_REACTIONS	CYP2C8 CYP2C9 CYP2D6	2.22e-05	11	74	3	M27130
Pathway	REACTOME_BIOSYNTHESIS_OF_SPECIALIZED_PRORESOLVING_MEDIATORS_SPMS	CYP2C8 CYP2C9 CYP2D6	1.27e-04	19	74	3	M27889
Pathway	WP_HIPPO_SIGNALING_REGULATION	MTOR PRKAA1 PRKAA2 CDH4 CDH18	1.62e-04	98	74	5	M39830
Pathway	WP_TAMOXIFEN_METABOLISM	CYP2C8 CYP2C9 CYP2D6	1.73e-04	21	74	3	M39631
Pathway	REACTOME_XENOBIOTICS	CYP2C8 CYP2C9 CYP2D6	2.94e-04	25	74	3	MM14846
Pathway	WP_OXIDATION_BY_CYTOCHROME_P450	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.10e-04	62	74	4	M39653
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.50e-04	64	74	4	M5650
Pathway	WP_EFFECT_OF_OMEGA3_PUFA_ON_HUNTINGTONS_DISEASE_PATHWAYS	SIN3A SLC12A2 MTOR PRKAA1 PRKAA2	3.99e-04	119	74	5	M48309
Pathway	KEGG_LINOLEIC_ACID_METABOLISM	CYP2C8 CYP2C9 CYP2C18	4.60e-04	29	74	3	M2920
Pathway	REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK	MTOR PRKAA1 PRKAA2	4.60e-04	29	74	3	M19861
Pathway	REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK	MTOR PRKAA1 PRKAA2	4.60e-04	29	74	3	MM14980
Pathway	WP_AUTOPHAGY	MTOR PRKAA1 PRKAA2	5.09e-04	30	74	3	M39904
Pathway	KEGG_DRUG_METABOLISM_CYTOCHROME_P450	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.50e-04	72	74	4	M9257
Pathway	WP_ARACHIDONATE_EPOXYGENASE_EPOXIDE_HYDROLASE	CYP2C8 CYP2C9	5.61e-04	7	74	2	M39515
Pathway	REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET	CYP2C8 CYP2C9	7.46e-04	8	74	2	M27135
Pathway	KEGG_MEDICUS_REFERENCE_STRAD_STK11_TSC_SIGNALING_PATHWAY	PRKAA1 PRKAA2	7.46e-04	8	74	2	M47916
Pathway	WP_TARGET_OF_RAPAMYCIN_SIGNALING	MTOR PRKAA1 PRKAA2	8.75e-04	36	74	3	M39635
Pathway	REACTOME_SYNTHESIS_OF_16_20_HYDROXYEICOSATETRAENOIC_ACIDS_HETE	CYP2C8 CYP2C9	9.56e-04	9	74	2	M27143
Pathway	KEGG_MEDICUS_REFERENCE_BMP9_10_SIGNALING_PATHWAY	ACVR2A BMP10	9.56e-04	9	74	2	M47822
Pathway	WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES_PATHWAY	CYP2C8 CYP2C18	9.56e-04	9	74	2	M39819
Pathway	WP_POLYCYSTIC_KIDNEY_DISEASE_PATHWAY	SLC12A2 MTOR PRKAA1 PRKAA2	1.03e-03	85	74	4	M48315
Pubmed	The human CYP2C locus: a prototype for intergenic and exon repetition splicing events.	CYP2C8 CYP2C9 CYP2C18	2.31e-08	3	100	3	10704292
Pubmed	Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.30e-08	14	100	4	19290787
Pubmed	Biochemistry and molecular biology of the human CYP2C subfamily.	CYP2C8 CYP2C9 CYP2C18	9.21e-08	4	100	3	7704034
Pubmed	Reduced AMPK-ACC and mTOR signaling in muscle from older men, and effect of resistance exercise.	MTOR PRKAA1 PRKAA2	9.21e-08	4	100	3	23000302
Pubmed	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	CYP2C8 CYP2C9 CYP2C18	9.21e-08	4	100	3	19706858
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.	CYP2C8 CYP2C9 CYP2C18	9.21e-08	4	100	3	2009263
Pubmed	Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.	CYP2C8 CYP2C9 CYP2C18	9.21e-08	4	100	3	21798861
Pubmed	Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.	CYP2C8 CYP2C9 CYP2D6	9.21e-08	4	100	3	16025294
Pubmed	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.	CYP2C8 CYP2C9 CYP2C18	9.21e-08	4	100	3	23755828
Pubmed	Prevalence of CYP450 gene variations in patients with type 2 diabetes.	CYP2C8 CYP2C9 CYP2D6	2.30e-07	5	100	3	20857895
Pubmed	Antagonistic control of muscle cell size by AMPK and mTORC1.	MTOR PRKAA1 PRKAA2	2.30e-07	5	100	3	21799304
Pubmed	The SLCO1B1*5 genetic variant is associated with statin-induced side effects.	CYP2C8 CYP2C9 CYP2D6	2.30e-07	5	100	3	19833260
Pubmed	Molecular genetics of the human cytochrome P450 monooxygenase superfamily.	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.01e-07	20	100	4	9890157
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	PPP2R2D LARS1 MCM2 ANKRD50 WDR19 TUBGCP6 CELSR3 MTA3 AUTS2 WDR90 ZNF687	3.80e-07	529	100	11	14621295
Pubmed	The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis.	MTOR PRKAA1 PRKAA2	4.58e-07	6	100	3	21941369
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SPEG TOR4A PLEKHM1 DIP2A THADA CELSR3 MTOR DIP2C WDR90 HERC1 MAPKBP1 TRAPPC9 TOP3A ZNF687 BAHCC1	6.28e-07	1105	100	15	35748872
Pubmed	Human transcription factor protein interaction networks.	TSHZ3 COPB2 LARS1 CDK11A ZNF217 SIN3A SEPTIN6 MTA3 ACTR6 AUTS2 OTUD4 NOC4L SPOP HERC1 QKI TRAPPC9 ZNF687	6.50e-07	1429	100	17	35140242
Pubmed	Metabolic regulator LKB1 is crucial for Schwann cell-mediated axon maintenance.	MTOR PRKAA1 PRKAA2	8.01e-07	7	100	3	25195104
Pubmed	AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.	MTOR PRKAA1 PRKAA2	8.01e-07	7	100	3	21258367
Pubmed	Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1).	MTOR PRKAA1 PRKAA2	1.28e-06	8	100	3	23184942
Pubmed	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.	CYP2C8 CYP2C9 CYP2D6	2.73e-06	10	100	3	19651758
Pubmed	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.	CYP2C8 CYP2C9 CYP2D6	2.73e-06	10	100	3	12865317
Pubmed	Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.	CYP2C8 CYP2C9 CYP2D6	3.74e-06	11	100	3	15469410
Pubmed	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.	CYP2C8 CYP2C9 CYP2D6	3.74e-06	11	100	3	15039299
Pubmed	Cross-linking mass spectrometry reveals the structural topology of peripheral NuRD subunits relative to the core complex.	ADNP2 SIN3A MTA3 ZNF687	4.41e-06	38	100	4	33283408
Pubmed	Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk.	CYP2C8 CYP2C9 CYP2D6	4.98e-06	12	100	3	20375710
Pubmed	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.	CYP2C8 CYP2C18 CYP2D6	4.98e-06	12	100	3	15319333
Pubmed	A glycolytic shift in Schwann cells supports injured axons.	MTOR PRKAA1 PRKAA2	4.98e-06	12	100	3	32807950
Pubmed	Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform.	CYP2C8 CYP2C9	8.18e-06	2	100	2	7574697
Pubmed	Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.	CYP2C9 CYP2D6	8.18e-06	2	100	2	15048614
Pubmed	Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells.	PRKAA1 PRKAA2	8.18e-06	2	100	2	21673972
Pubmed	Fat adaptation followed by carbohydrate restoration increases AMPK activity in skeletal muscle from trained humans.	PRKAA1 PRKAA2	8.18e-06	2	100	2	18801964
Pubmed	Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative.	CYP2C8 CYP2C9	8.18e-06	2	100	2	30562214
Pubmed	Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.	CYP2C8 CYP2C9	8.18e-06	2	100	2	26122864
Pubmed	Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status.	PRKAA1 PRKAA2	8.18e-06	2	100	2	21947382
Pubmed	Hypoglycemia-Sensing Neurons of the Ventromedial Hypothalamus Require AMPK-Induced Txn2 Expression but Are Dispensable for Physiological Counterregulation.	PRKAA1 PRKAA2	8.18e-06	2	100	2	32839348
Pubmed	Loss of AMP-activated protein kinase alpha2 subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia.	PRKAA1 PRKAA2	8.18e-06	2	100	2	20465544
Pubmed	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.	CYP2C9 CYP2D6	8.18e-06	2	100	2	14726986
Pubmed	Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase.	PRKAA1 PRKAA2	8.18e-06	2	100	2	19236843
Pubmed	Lysosomal dysfunction and autophagy blockade contribute to autophagy-related cancer suppressing peptide-induced cytotoxic death of cervical cancer cells through the AMPK/mTOR pathway.	MTOR PRKAA1	8.18e-06	2	100	2	32962728
Pubmed	Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.	MTOR PRKAA1	8.18e-06	2	100	2	26648451
Pubmed	Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle.	PRKAA1 PRKAA2	8.18e-06	2	100	2	23905686
Pubmed	Cloning, genomic organization and expression pattern of a novel Drosophila gene, the disco-interacting protein 2 (dip2), and its murine homolog.	DIP2A DIP2C	8.18e-06	2	100	2	12137943
Pubmed	Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.	CYP2C8 CYP2C9	8.18e-06	2	100	2	12435384
Pubmed	Inducible deletion of skeletal muscle AMPKα reveals that AMPK is required for nucleotide balance but dispensable for muscle glucose uptake and fat oxidation during exercise.	PRKAA1 PRKAA2	8.18e-06	2	100	2	32504885
Pubmed	Adipose tissue-specific knockout of AMPKα1/α2 results in normal AICAR tolerance and glucose metabolism.	PRKAA1 PRKAA2	8.18e-06	2	100	2	31540695
Pubmed	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.	CYP2C8 CYP2C9	8.18e-06	2	100	2	18694831
Pubmed	Functional differences between AMPK α1 and α2 subunits in osteogenesis, osteoblast-associated induction of osteoclastogenesis, and adipogenesis.	PRKAA1 PRKAA2	8.18e-06	2	100	2	27600021
Pubmed	Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice.	PRKAA1 PRKAA2	8.18e-06	2	100	2	23486478
Pubmed	Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle.	PRKAA1 PRKAA2	8.18e-06	2	100	2	15878932
Pubmed	Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.	CYP2C9 CYP2D6	8.18e-06	2	100	2	37747773
Pubmed	AMPK activation regulates neuronal structure in developing hippocampal neurons.	PRKAA1 PRKAA2	8.18e-06	2	100	2	24295634
Pubmed	AMP kinase regulation of sugar transport in brain capillary endothelial cells during acute metabolic stress.	PRKAA1 PRKAA2	8.18e-06	2	100	2	22763120
Pubmed	T-bet antagonizes mSin3a recruitment and transactivates a fully methylated IFN-gamma promoter via a conserved T-box half-site.	TBX21 SIN3A	8.18e-06	2	100	2	15684083
Pubmed	AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase.	PRKAA1 PRKAA2	8.18e-06	2	100	2	22233421
Pubmed	Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.	CYP2C9 CYP2C18	8.18e-06	2	100	2	8333835
Pubmed	The energy sensor AMPK regulates Hedgehog signaling in human cells through a unique Gli1 metabolic checkpoint.	PRKAA1 PRKAA2	8.18e-06	2	100	2	26843621
Pubmed	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.	CYP2C8 CYP2C9	8.18e-06	2	100	2	16372821
Pubmed	Phosphorylation and activation of AMP-activated protein kinase (AMPK) by metformin in the human ovary requires insulin.	PRKAA1 PRKAA2	8.18e-06	2	100	2	21209024
Pubmed	Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice.	PRKAA1 PRKAA2	8.18e-06	2	100	2	24855056
Pubmed	AMPKα is essential for acute exercise-induced gene responses but not for exercise training-induced adaptations in mouse skeletal muscle.	PRKAA1 PRKAA2	8.18e-06	2	100	2	26419588
Pubmed	Autophagy and mitochondrial biogenesis impairment contribute to age-dependent liver injury in experimental sepsis: dysregulation of AMP-activated protein kinase pathway.	PRKAA1 PRKAA2	8.18e-06	2	100	2	28974562
Pubmed	Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models.	PRKAA1 PRKAA2	8.18e-06	2	100	2	12546688
Pubmed	Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.	CYP2C8 CYP2C9	8.18e-06	2	100	2	18548238
Pubmed	AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress.	PRKAA1 PRKAA2	8.18e-06	2	100	2	12788940
Pubmed	Skeletal muscle-specific inducible AMPKα1/α2 knockout mice develop muscle weakness, glycogen depletion, and fibrosis that persists during disuse atrophy.	PRKAA1 PRKAA2	8.18e-06	2	100	2	38019084
Pubmed	The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.	PRKAA1 PRKAA2	8.18e-06	2	100	2	34347929
Pubmed	Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling.	MTOR PRKAA1	8.18e-06	2	100	2	28147330
Pubmed	Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK.	PRKAA1 PRKAA2	8.18e-06	2	100	2	31693892
Pubmed	Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.	CYP2C8 CYP2C9	8.18e-06	2	100	2	14646690
Pubmed	Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.	PRKAA1 PRKAA2	8.18e-06	2	100	2	32213711
Pubmed	AMPK knockdown in placental trophoblast cells results in altered morphology and function.	PRKAA1 PRKAA2	8.18e-06	2	100	2	25003940
Pubmed	AMPK-α1 or AMPK-α2 Deletion in Smooth Muscles Does Not Affect the Hypoxic Ventilatory Response or Systemic Arterial Blood Pressure Regulation During Hypoxia.	PRKAA1 PRKAA2	8.18e-06	2	100	2	29928235
Pubmed	Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.	CYP2C8 CYP2C18	8.18e-06	2	100	2	10487415
Pubmed	[AMPK as a Metabolic Intersection between Diet and Physical Exercise].	PRKAA1 PRKAA2	8.18e-06	2	100	2	30270274
Pubmed	The role of diacylglycerol kinase ζ and phosphatidic acid in the mechanical activation of mammalian target of rapamycin (mTOR) signaling and skeletal muscle hypertrophy.	DGKZ MTOR	8.18e-06	2	100	2	24302719
Pubmed	Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.	CYP2C8 CYP2C9	8.18e-06	2	100	2	19480553
Pubmed	AMPK regulates circadian rhythms in a tissue- and isoform-specific manner.	PRKAA1 PRKAA2	8.18e-06	2	100	2	21483791
Pubmed	AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass.	PRKAA1 PRKAA2	8.18e-06	2	100	2	20399918
Pubmed	Conditional disruption of AMP kinase in dopaminergic neurons promotes Parkinson's disease-associated phenotypes in vivo.	PRKAA1 PRKAA2	8.18e-06	2	100	2	34767944
Pubmed	Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily.	CYP2C8 CYP2C9	8.18e-06	2	100	2	15766564
Pubmed	Involvement of AMPK in regulating slow-twitch muscle atrophy during hindlimb unloading in mice.	PRKAA1 PRKAA2	8.18e-06	2	100	2	26244519
Pubmed	Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5'-AMP-activated protein kinase-dependent manner.	PRKAA1 PRKAA2	8.18e-06	2	100	2	12091379
Pubmed	Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid.	DGKZ MTOR	8.18e-06	2	100	2	15632115
Pubmed	A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators.	PRKAA1 PRKAA2	8.18e-06	2	100	2	24665903
Pubmed	Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort.	CYP2C8 CYP2C9	8.18e-06	2	100	2	21047199
Pubmed	Role of AMPK throughout meiotic maturation in the mouse oocyte: evidence for promotion of polar body formation and suppression of premature activation.	PRKAA1 PRKAA2	8.18e-06	2	100	2	20830737
Pubmed	Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.	CYP2C8 CYP2C9	8.18e-06	2	100	2	16646575
Pubmed	CCCP induces autophagy in an AMPK-independent manner.	PRKAA1 PRKAA2	8.18e-06	2	100	2	22119190
Pubmed	Protein expression alteration in hippocampus upon genetic repression of AMPKα isoforms.	PRKAA1 PRKAA2	8.18e-06	2	100	2	33492732
Pubmed	cDNA and amino acid sequences of two members of the human P450IIC gene subfamily.	CYP2C8 CYP2C9	8.18e-06	2	100	2	3697070
Pubmed	Loss of hepatic AMP-activated protein kinase impedes the rate of glycogenolysis but not gluconeogenic fluxes in exercising mice.	PRKAA1 PRKAA2	8.18e-06	2	100	2	29038293
Pubmed	Different expression of the catalytic alpha subunits of the AMP activated protein kinase--an immunohistochemical study in human tissue.	PRKAA1 PRKAA2	8.18e-06	2	100	2	21432774
Pubmed	Aerobic exercise intensity does not affect the anabolic signaling following resistance exercise in endurance athletes.	MTOR PRKAA2	8.18e-06	2	100	2	34031501
Pubmed	AMP-activated protein kinase alpha2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle.	PRKAA1 PRKAA2	8.18e-06	2	100	2	16186119
Pubmed	Role of adenosine 5'-monophosphate-activated protein kinase in α-linolenic acid-induced intestinal lipid metabolism.	PRKAA1 PRKAA2	8.18e-06	2	100	2	26268732
Pubmed	Global variation in CYP2C8-CYP2C9 functional haplotypes.	CYP2C8 CYP2C9	8.18e-06	2	100	2	19381162
Pubmed	AMP-activated Kinase (AMPK) Promotes Innate Immunity and Antiviral Defense through Modulation of Stimulator of Interferon Genes (STING) Signaling.	PRKAA1 PRKAA2	8.18e-06	2	100	2	27879319
Pubmed	METABOLISM. S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction.	ERN1 NOS2	8.18e-06	2	100	2	26228140
Pubmed	AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity.	PRKAA1 PRKAA2	8.18e-06	2	100	2	24652947
Cytoband	Ensembl 112 genes in cytogenetic band chr20q13	ZNF217 R3HDML ZBTB46 CTCFL OSBPL2 ABHD16B CDH4	4.05e-05	422	100	7	chr20q13
GeneFamily	Cytochrome P450 family 2	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.04e-05	35	71	4	1001
GeneFamily	WD repeat domain containing	PPP2R2D COPB2 WDR19 WDR90 HERC1 MAPKBP1	5.70e-04	262	71	6	362
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	TSHZ3 ADNP2	1.54e-03	15	71	2	529
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	TSHZ3 ZNF560 ZNF549 ADNP2 ZNF217 ZNF623 ZBTB46 CTCFL ZNF469	1.92e-03	718	71	9	28
GeneFamily	Cadherin related	CDHR5 CLSTN2	1.99e-03	17	71	2	24
GeneFamily	Protein tyrosine phosphatases, non-receptor type	PTPN13 PTPN14	2.23e-03	18	71	2	812
GeneFamily	Aminoacyl tRNA synthetases, Class II	AARS1 FARS2	2.49e-03	19	71	2	132
Coexpression	GSE3982_BCELL_VS_CENT_MEMORY_CD4_TCELL_DN	RASGRF1 PCLO ADNP2 ITGA9 PTPN13 PRKAA2 AUTS2	1.12e-05	198	100	7	M5545
Coexpression	GSE22611_NOD2_VS_MUTANT_NOD2_TRANSDUCED_HEK293T_CELL_UP	COPB2 ACVR2A THADA SLC12A2 PRKAA1 AHSG HERC1	1.15e-05	199	100	7	M8164
Coexpression	NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON	ZNF217 ZBTB46 CTCFL OSBPL2 ABHD16B CDH4	2.34e-05	149	100	6	M18973
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGEF28 ERN1 ITGA9 PTPN13 AUTS2 CDH18	3.98e-06	186	100	6	e83718fabb057100835d3357df407f283d23fe16
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PRUNE2 ARHGEF28 PCLO PTPN13 PRKAA2 DIP2C	4.92e-06	193	100	6	3866667dd221612589ae50f5c52f73a183a49ce6
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	DYM ARHGEF28 AUTS2 DIP2C HERC1 TRAPPC9	5.86e-06	199	100	6	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
Computational	Cytochrome P450.	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.40e-06	14	68	4	MODULE_106
Computational	Neighborhood of TST	CYP2C8 CYP2C9 CYP2D6 CDHR5 AHSG SARDH	4.78e-05	104	68	6	GNF2_TST
Computational	Neighborhood of LCAT	CYP2C8 CYP2C9 CYP2D6 CDHR5 AHSG SARDH	1.27e-04	124	68	6	GNF2_LCAT
Computational	Neighborhood of HPN	CYP2C8 CYP2C9 CYP2D6 CDHR5 AHSG SARDH	1.95e-04	134	68	6	GNF2_HPN
Computational	Neighborhood of HPX	CYP2C8 CYP2C9 CYP2D6 CDHR5 AHSG SARDH	2.03e-04	135	68	6	GNF2_HPX
Computational	Genes in the cancer module 135.	CYP2C8 CYP2C18 CYP2D6	5.04e-04	25	68	3	MODULE_135
Computational	Neighborhood of GSTM1	CYP2C8 CYP2C9 CYP2D6 CDHR5 SARDH	6.14e-04	109	68	5	GNF2_GSTM1
Drug	2'-(glutathion-S-yl)-deschlorodiclofenac	CYP2C8 CYP2C9 CYP2C18 CYP2D6	4.61e-07	15	100	4	ctd:C586542
Drug	bufuralol	CYP2C8 CYP2C9 CYP2D6	8.17e-07	5	100	3	ctd:C010831
Drug	taxol	FOXRED1 CYP2C8 CYP2C9 CYP2C18 CYP2D6 SYT9 PKDREJ SLC12A2 MTOR ACTR6 NOS2 TOP3A ALPP	1.06e-06	560	100	13	CID000004666
Drug	3C etc	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.61e-06	20	100	4	CID000164045
Drug	4',5-dihydroxydiclofenac	CYP2C8 CYP2C9 CYP2C18	1.63e-06	6	100	3	CID003052567
Drug	3'-hydroxydiclofenac	CYP2C8 CYP2C9 CYP2C18	1.63e-06	6	100	3	CID000112230
Drug	diosmetin	CYP2C8 CYP2C9 CYP2C18 CYP2D6 AHSG NOS2	2.04e-06	85	100	6	CID005281612
Drug	Enoxacin [74011-58-8]; Up 200; 12.4uM; MCF7; HT_HG-U133A	PRUNE2 CYP2C9 ARHGEF28 SPEG PCLO SEPTIN6 CDH4 NOS2	2.57e-06	197	100	8	5616_UP
Drug	16-O-demethylaconitine	CYP2C8 CYP2C9 CYP2D6	2.84e-06	7	100	3	ctd:C486136
Drug	5-fluorotryptamine	CYP2C8 CYP2C9 CYP2D6	2.84e-06	7	100	3	ctd:C034536
Drug	norfluoxetine	CYP2C9 CYP2D6 ALPP	2.84e-06	7	100	3	ctd:C036139
Drug	Docetaxel trihydrate	CYP2C8 CYP2C9 CYP2C18 CYP2D6 ITGA9 SLC12A2 MTOR TOP3A	3.09e-06	202	100	8	CID000003143
Drug	aniline	CYP2C8 CYP2C9 CYP2C18 CYP2D6 SCYL3 CLSTN2 EPX	3.12e-06	142	100	7	CID000006115
Drug	AC1L1BEQ	CYP2C8 CYP2C9 CYP2C18 CYP2D6 SLC12A2 NOS2	3.45e-06	93	100	6	CID000001407
Drug	ebastine	CYP2C8 CYP2D6 LARS1 PLEKHM1	4.13e-06	25	100	4	CID000003191
Drug	chloroacetyl chloride	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2	4.32e-06	55	100	5	CID000006577
Drug	5-bromotryptamine	CYP2C8 CYP2C9 CYP2D6	4.53e-06	8	100	3	ctd:C040997
Drug	1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid	CYP2C8 CYP2C9 CYP2D6	4.53e-06	8	100	3	ctd:C585955
Drug	1,4-naphthoquinone	CYP2C8 CYP2C9 CYP2C18 CYP2D6	4.86e-06	26	100	4	ctd:C035342
Drug	BP-9,10-oxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.69e-06	27	100	4	CID000037456
Drug	Brn 4136738	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.69e-06	27	100	4	CID000050331
Drug	licochalcone A	CYP2C8 CYP2C9 CYP2D6 NOS2	5.69e-06	27	100	4	ctd:C070840
Drug	C14845	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.69e-06	27	100	4	CID011954064
Drug	9-OH-BaP-4,5-oxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.61e-06	28	100	4	CID000115064
Drug	1,1-dichloroethylene	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2	6.66e-06	60	100	5	CID000006366
Drug	4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide	CYP2C9 CYP2C18 CYP2D6	6.77e-06	9	100	3	ctd:C545880
Drug	Tryptamines	CYP2C8 CYP2C9 CYP2D6	6.77e-06	9	100	3	ctd:D014363
Drug	5-chlorotryptamine	CYP2C8 CYP2C9 CYP2D6	6.77e-06	9	100	3	ctd:C529169
Drug	3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate	CYP2C8 CYP2C9 CYP2D6	6.77e-06	9	100	3	ctd:C109602
Drug	trichloroacetic acid	CYP2C8 CYP2C9 CYP2C18 CYP2D6 ITGA9 ITM2B	7.79e-06	107	100	6	CID000006421
Drug	chlorzoxazone	CYP2C8 CYP2C9 CYP2C18 CYP2D6 NOS2	8.49e-06	63	100	5	CID000002733
Drug	19-hydroxytestosterone	CYP2C8 CYP2C9 CYP2C18 CYP2D6	8.79e-06	30	100	4	CID000150968
Drug	11-H-14,15-EETA	CYP2C8 CYP2C9 CYP2C18 CYP2D6	8.79e-06	30	100	4	CID011954058
Drug	aminopyrine	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2 EPX SARDH	1.06e-05	171	100	7	CID000006009
Drug	BP-7,8-oxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.15e-05	32	100	4	CID000037455
Drug	trans-1,2-dihydro-1,2-naphthalenediol	CYP2C8 CYP2C9 CYP2D6	1.32e-05	11	100	3	ctd:C507866
Drug	8(9)-EET	CYP2C8 CYP2C9 CYP2C18 CYP2D6 SLC12A2	1.33e-05	69	100	5	CID000001901
Drug	8-MOP	CYP2C8 CYP2C9 DYM CYP2C18 CYP2D6 TOP3A	1.37e-05	118	100	6	CID000004114
Drug	benzphetamine	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2 SARDH	1.43e-05	119	100	6	CID000002341
Drug	12(13)-EpOME	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.47e-05	34	100	4	CID000001416
Drug	TCEO	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.47e-05	34	100	4	CID000028167
Drug	AC1O5XSP	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.47e-05	34	100	4	CID006442739
Drug	AC1L1CJI	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.65e-05	35	100	4	CID000001929
Drug	5-hydroxydiclofenac	CYP2C8 CYP2C9 CYP2C18	1.76e-05	12	100	3	CID003052566
Drug	desethylamodiaquine	CYP2C8 CYP2C9 CYP2D6	1.76e-05	12	100	3	ctd:C047386
Drug	norclozapine	CYP2C8 CYP2C9 CYP2D6	1.76e-05	12	100	3	ctd:C058272
Drug	15-H-11,12-EETA	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.85e-05	36	100	4	CID011954042
Drug	AC1L3NGJ	CYP2C8 CYP2C9 CYP2C18 CYP2D6	1.85e-05	36	100	4	CID000092121
Drug	BLX 1002	PRKAA1 PRKAA2	1.91e-05	2	100	2	ctd:C542815
Drug	AC1L18GM	CYP2C8 CYP2C9 CYP2D6	2.28e-05	13	100	3	CID000000092
Drug	clozapine N-oxide	CYP2C8 CYP2C9 DYM	2.28e-05	13	100	3	CID000036727
Drug	C20H32O4	CYP2C8 CYP2C9 CYP2C18 CYP2D6 EPX	2.42e-05	78	100	5	CID000001440
Drug	11,14,15-THET	CYP2C8 CYP2C9 CYP2C18 CYP2D6	2.56e-05	39	100	4	CID006439531
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; MCF7; HT_HG-U133A	SPEG EPX CEP350 BMP10 PRKAA2 AHSG QKI	2.74e-05	198	100	7	4410_UP
Drug	furafylline	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.13e-05	41	100	4	CID000003433
Drug	11,12,15-trihydroxyeicosatrienoic acid	CYP2C8 CYP2C9 CYP2C18 CYP2D6	3.45e-05	42	100	4	CID006439610
Drug	lumiracoxib	CYP2C9 DYM TBX21 PMEL	3.45e-05	42	100	4	CID000151166
Drug	4-hydroxymephenytoin	CYP2C8 CYP2C9 CYP2D6	3.60e-05	15	100	3	CID000119507
Drug	sulfaphenazole	CYP2C8 CYP2C9 CYP2C18 CYP2D6	4.16e-05	44	100	4	CID000005335
Drug	polybrominated biphenyl	CYP2C8 CYP2C9 CYP2C18 CYP2D6	4.16e-05	44	100	4	CID000042948
Drug	Amodiaquine	CYP2C8 CYP2C9 CYP2D6	4.42e-05	16	100	3	ctd:D000655
Drug	1-phenylazo-2-naphthol	CYP2C8 CYP2C9 CYP2D6	4.42e-05	16	100	3	ctd:C024336
Drug	1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane	CYP2C9 CYP2C18 CYP2D6	4.42e-05	16	100	3	ctd:C495657
Drug	naphthalene-1,2-dihydrodiol	CYP2C8 CYP2C9 CYP2C18 CYP2D6	4.55e-05	45	100	4	CID000000362
Drug	14(15)-EpETrE	CYP2C8 CYP2C9 CYP2C18 CYP2D6 SLC12A2	4.58e-05	89	100	5	CID000001431
Drug	parathion	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2	5.10e-05	91	100	5	CID000000991
Drug	phenytoin	CYP2C8 CYP2C9 CYP2C18 CYP2D6 AHSG QKI NOS2	5.19e-05	219	100	7	CID000001775
Drug	diosmetin	CYP2C8 CYP2C9 NOS2	5.35e-05	17	100	3	ctd:C039602
Drug	noralfentanil	CYP2C8 CYP2C9 CYP2D6	5.35e-05	17	100	3	CID000162172
Drug	dimemorfan	CYP2C9 CYP2D6 NOS2	5.35e-05	17	100	3	ctd:C012621
Drug	C14802	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.40e-05	47	100	4	CID011954053
Drug	Cyclohexenes	CYP2C8 CYP2C9	5.71e-05	3	100	2	ctd:D053138
Drug	ortho-Aminobenzoates	CYP2C8 CYP2C9	5.71e-05	3	100	2	ctd:D062367
Drug	2-ethyl-1,3-hexanediol	PLEKHM1 DMPK	5.71e-05	3	100	2	CID000007211
Drug	tulipanin	ITGA9 MTOR	5.71e-05	3	100	2	CID000192918
Drug	nitro-L	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.88e-05	48	100	4	CID000006849
Drug	C14800	CYP2C8 CYP2C9 CYP2C18 CYP2D6	5.88e-05	48	100	4	CID011954051
Drug	ethoxyresorufin	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2	6.26e-05	95	100	5	CID000003294
Drug	19-HETE	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.38e-05	49	100	4	CID006439528
Drug	bromobenzene-3,4-oxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.38e-05	49	100	4	CID000108121
Drug	Azamulinum	CYP2C8 CYP2C9 CYP2C18	6.39e-05	18	100	3	CID003086060
Drug	D 703	CYP2C8 CYP2C9 CYP2C18	6.39e-05	18	100	3	CID000054088
Drug	Heme	CYP2C8 CYP2C9 NOS2	6.39e-05	18	100	3	DB03014
Drug	bromobenzene-2,3-oxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.91e-05	50	100	4	CID003036760
Drug	6-hydroxymelatonin	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.91e-05	50	100	4	CID000001864
Drug	1,1-dichloroethylene epoxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	6.91e-05	50	100	4	CID000119521
Drug	bromobenzene	CYP2C8 CYP2C9 CYP2C18 CYP2D6 CLSTN2	6.92e-05	97	100	5	CID000007961
Drug	naphthalene epoxide	CYP2C8 CYP2C9 CYP2C18 CYP2D6	7.47e-05	51	100	4	CID000108063
Drug	hydroxytolbutamide	CYP2C8 CYP2C9 CYP2C18	7.57e-05	19	100	3	CID000003656
Drug	D 617	CYP2C8 CYP2C9 CYP2C18	7.57e-05	19	100	3	CID000093168
Drug	antipyrine	CYP2C9 CYP2C18 CYP2D6 CLSTN2	8.70e-05	53	100	4	CID000002206
Drug	9-hydroxybenzo(a)pyrene	CYP2C8 CYP2C9 CYP2C18 CYP2D6	8.70e-05	53	100	4	CID000028598
Drug	Domperidone	CYP2C8 CYP2D6 NOS2	8.88e-05	20	100	3	ctd:D004294
Drug	3-methoxymorphinan	CYP2C8 CYP2C9 CYP2D6	8.88e-05	20	100	3	CID000001671
Drug	dihydrocapsaicin	CYP2C9 CYP2D6 ERN1	8.88e-05	20	100	3	ctd:C012906
Drug	dichloroacetaldehyde	CYP2C8 CYP2C9 CYP2C18 CYP2D6	9.36e-05	54	100	4	CID000006576
Drug	racemethorphan	CYP2C8 CYP2C9 CYP2C18 CYP2D6 DMPK	1.10e-04	107	100	5	CID000003008
Drug	thiocoraline	CYP2C8 CYP2C9	1.14e-04	4	100	2	ctd:C109005
Drug	1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea	CYP2C9 CYP2D6	1.14e-04	4	100	2	ctd:C558737
Drug	4-isopropylphenol	CYP2C8 CYP2C9	1.14e-04	4	100	2	ctd:C028690
Disease	microcephaly (implicated_via_orthology)	AARS1 COPB2 AUTS2 MAPKBP1	4.15e-06	32	100	4	DOID:10907 (implicated_via_orthology)
Disease	Gastric Adenocarcinoma	ERN1 SPEG ACVR2A PRKAA2	1.66e-05	45	100	4	C0278701
Disease	X-21258 measurement	CYP2C9 CYP2C18	3.40e-05	3	100	2	EFO_0800802
Disease	Impaired glucose tolerance	SLC12A2 PRKAA1 PRKAA2	8.23e-05	25	100	3	C0271650
Disease	axial length measurement	RASGRF1 ZNF469 ADAMTS16 CDH4	1.39e-04	77	100	4	EFO_0005318
Disease	Major Depressive Disorder	CYP2C9 CYP2D6 PCLO TBX21 MTOR QKI	1.83e-04	243	100	6	C1269683
Disease	Drug toxicity	CYP2C8 CYP2C9 CYP2D6 AHSG	1.95e-04	84	100	4	C0013221
Disease	Adverse reaction to drug	CYP2C8 CYP2C9 CYP2D6 AHSG	1.95e-04	84	100	4	C0041755
Disease	glycine conjugate of C10H14O2 (1) measurement	CYP2C9 CYP2C18	2.36e-04	7	100	2	EFO_0800655
Disease	Nephronophthisis, familial juvenile	WDR19 MAPKBP1	2.36e-04	7	100	2	C1855681
Disease	colon cancer (is_implicated_in)	ACVR2A PTPN13 PRKAA1	2.49e-04	36	100	3	DOID:219 (is_implicated_in)
Disease	Unipolar Depression	CYP2C9 CYP2D6 PCLO TBX21 MTOR QKI	2.58e-04	259	100	6	C0041696
Disease	type 2 diabetes mellitus (is_implicated_in)	CYP2C9 MTOR PRKAA2 AHSG NOS2	2.98e-04	171	100	5	DOID:9352 (is_implicated_in)
Disease	AUTISM, SUSCEPTIBILITY TO, 15	SIN3A AUTS2	3.14e-04	8	100	2	C2677504
Disease	Acute kidney injury	CYP2C9 CYP2D6 AHSG NOS2	3.94e-04	101	100	4	C2609414
Disease	Acute Kidney Insufficiency	CYP2C9 CYP2D6 AHSG NOS2	3.94e-04	101	100	4	C1565662
Disease	Kidney Failure, Acute	CYP2C9 CYP2D6 AHSG NOS2	3.94e-04	101	100	4	C0022660
Disease	Oxidative Phosphorylation Deficiencies	FOXRED1 NOS2	4.03e-04	9	100	2	C0949856
Disease	Mitochondrial Respiratory Chain Deficiencies	FOXRED1 NOS2	4.03e-04	9	100	2	C0949857
Disease	Electron Transport Chain Deficiencies, Mitochondrial	FOXRED1 NOS2	4.03e-04	9	100	2	C0949855
Disease	interleukin-6 measurement, response to stimulus	MUC16 ABHD16B	6.13e-04	11	100	2	EFO_0004810, GO_0050896
Disease	age-related hearing impairment	ARHGEF28 CLSTN2 THADA PTPN14 AUTS2 CDH18	8.40e-04	324	100	6	EFO_0005782
Disease	ecosanoids measurement	CYP2C8 CYP2C9 CYP2C18	8.72e-04	55	100	3	EFO_0020044
Disease	urinary nitrogen measurement	TUBGCP6 TRAPPC9	1.01e-03	14	100	2	EFO_0005190
Disease	Manganese Poisoning	CYP2D6 NOS2	1.01e-03	14	100	2	C0677050
Disease	16a-hydroxy DHEA 3-sulfate measurement	CYP2C8 CYP2C9	1.16e-03	15	100	2	EFO_0800301
Disease	Cerebrovascular accident	PRKAA2 ITM2B NOS2	1.24e-03	62	100	3	C0038454
Disease	andro steroid monosulfate C19H28O6S (1) measurement	CYP2C8 CYP2C9	1.32e-03	16	100	2	EFO_0800305
Disease	metabolonic lactone sulfate measurement	CYP2C9 CYP2C18	1.87e-03	19	100	2	EFO_0800659
Disease	Nephritis, Tubulointerstitial	CYP2C9 CYP2D6	2.29e-03	21	100	2	C0041349
Disease	Colorectal Carcinoma	ZNF560 SYT9 ZNF217 CLSTN2 ARHGEF1 VRTN DIP2C QKI	2.69e-03	702	100	8	C0009402
Disease	Epilepsy, Cryptogenic	ERN1 SLC12A2 AUTS2	2.76e-03	82	100	3	C0086237
Disease	response to selective serotonin reuptake inhibitor	TSHZ3 AUTS2 NOC4L	2.76e-03	82	100	3	EFO_0005658
Disease	Awakening Epilepsy	ERN1 SLC12A2 AUTS2	2.76e-03	82	100	3	C0751111
Disease	Aura	ERN1 SLC12A2 AUTS2	2.76e-03	82	100	3	C0236018
Disease	sudden cardiac arrest	CLSTN2 SIN3A CDH4	2.85e-03	83	100	3	EFO_0004278
Disease	Nephritis, Interstitial	CYP2C9 CYP2D6	2.99e-03	24	100	2	C0027707
Disease	unipolar depression, response to selective serotonin reuptake inhibitor	CYP2C9 CYP2D6	2.99e-03	24	100	2	EFO_0003761, EFO_0005658
Disease	Autism Spectrum Disorders	TSHZ3 SIN3A DIP2A	3.05e-03	85	100	3	C1510586
Disease	osteonecrosis	CYP2C8 QKI	3.24e-03	25	100	2	EFO_0004259
Disease	S-6-hydroxywarfarin to S-warfarin ratio measurement	CYP2C8 CYP2C9 CYP2C18	3.36e-03	88	100	3	EFO_0803332

Protein segments in the cluster

Peptide	Gene	Start	Entry
EIISYRQLHVMDETH	ACTR6	186	Q9GZN1
ECLERRQMLHHTASY	BAHCC1	336	Q9P281
YEARERHVAERLLMH	ARHGEF1	186	Q92888
SDLRVHMRNLHAYSA	CTCFL	441	Q8NI51
RVHMFEAHSDYIRCI	COPB2	91	P35606
AVDYCHRHMVVHRDL	PRKAA2	126	P54646
HIAETMARGLAYLHE	ACVR2A	291	P27037
DRSHMPYTDAVVHEI	CYP2C8	341	P10632
MESRPVETHQVHEYL	PPP2R2D	321	Q66LE6
LIAAAYMGHREIVEH	ANKRD50	681	Q9ULJ7
YRITNHSHFRMEGEV	CDHR5	401	Q9HBB8
SMSRYEQVLHHIRYR	CLSTN2	741	Q9H4D0
RGDYVSHEIMHHQRR	ADAMTS16	71	Q8TE57
NAMDVVVEYALHRLH	ABHD16B	221	Q9H3Z7
MYHILTSDIHRDLEN	ADNP2	231	Q6IQ32
VENEIYSESHRVHRM	RCC1L	211	Q96I51
HVEVRMACIHYLREN	OTUD4	61	Q01804
HDMRVHPYQRIVTAD	QKI	321	Q96PU8
IRMAEAHARIHLRDY	MCM2	771	P49736
YDGSHQRHVMIAERI	ARHGEF28	36	Q8N1W1
REMFEHICRHVRYST	NOS2	221	P35228
IETHIHVSTARMAYS	MUC16	1286	Q8WXI7
ISMREDHSFHVRYRM	GPSM2	6	P81274
DHSFHVRYRMEASCL	GPSM2	11	P81274
SYLIHEHMVITDRIE	ITM2B	196	Q9Y287
GEIMHTRYELVTTVH	ARRDC5	286	A6NEK1
DVSTMHRRELEHCYR	HERC1	3566	Q15751
QHAMSDSEAYHLRRE	PCLO	4426	Q9Y6V0
AATRTVVRAADYMHV	EPX	81	P11678
RTRHHVYVTAALMEY	CSTF3	406	Q12996
HMLREDYEHTRLHSV	AUTS2	1156	Q8WXX7
AVYVGRMERVARHSS	TUBGCP6	641	Q96RT7
AVMAYDRHVAVSDRL	OR2F2	116	O95006
MAIDSVHRLGYVHRD	DMPK	181	Q09013
EHVRMVLLSHIEAYV	SCYL3	351	Q8IZE3
HHESRAYRALTETIM	ALPP	341	P05187
MEETCRHYVAHVKRR	ITGA9	551	Q13797
HHEEVIMAELRLYTL	BMP10	136	O95393
VEERNSHHVYMALII	DYM	386	Q7RTS9
LAHTYRAMELCSHER	ERN1	941	O75460
RAHYDLRHTFMGVVS	AHSG	311	P02765
AHMPYTTAVIHEVQR	CYP2D6	351	P10635
IHEVHVKMDRSLEYQ	FOXRED1	266	Q96CU9
VTRPMDREEHASYHL	CDH4	231	P55283
HHRMAAELSYLNAIE	CEP350	1326	Q5VT06
TTVYVDMRALRHDRV	DIP2C	1316	Q9Y2E4
RREVSAHHRTMREDY	CDK11A	196	Q9UQ88
HHVVRKTTLYDMDVE	MAPKBP1	611	O60336
LHNMDREAREHYSVV	CDH18	221	Q13634
DRSHMPYTDAVVHEI	CYP2C18	341	P33260
DHRMNHFRVYSDITL	FAM183BP	106	Q6ZVS7
DRSHMPYTDAVVHEV	CYP2C9	341	P11712
IQVSRVSMHDYEALH	DGKZ	646	Q13574
TTVYVDMRALRHDRV	DIP2A	1331	Q14689
MERHYLRVTAQDHGS	CELSR3	396	Q9NYQ7
HRAMRVAHLELATYE	FMR1NB	16	Q8N0W7
RYHTMQAAVDAVARV	NOC4L	181	Q9BVI4
RHISVRDMNALLDYH	R3HDML	56	Q9H3Y0
DDLLTFISYMRHIHR	PTPN13	2386	Q12923
YRITCHTVMEVLREH	MTOR	2396	P42345
DITLFHAMDTLYRHS	MTA3	231	Q9BTC8
ASLYEHVERMHLIGR	PLEKHM1	906	Q9Y4G2
LIYSMSQEEHLHHVR	RTL1	736	A6NKG5
HLSIAVMDYDRVGHN	SYT9	436	Q86SS6
HSPVYHSREMAARAL	THADA	1356	Q6YHU6
EDRHALHMDYILVNR	PRUNE2	2541	Q8WUY3
IHSSQYLMEVTHDLR	LARS1	896	Q9P2J5
YRDEMDQHLRGHVIV	PKDREJ	1206	Q9NTG1
MRADYIPSHRHSAII	PTPN14	421	Q15678
MYRRTALLRAHQSHE	SIN3A	1186	Q96ST3
HDSRMHYGNRVTDLI	TENM2	51	Q9NT68
ETHVMDYRALVHERD	PSME2	181	Q9UL46
EESIRYSRQHHSIQM	WHAMM	501	Q8TF30
LHHMEVEFAIRVYRR	WDR19	686	Q8NEZ3
THTMEVTVYHRRGSR	PMEL	181	P40967
HASYRTLATEHEALM	RASGRF1	126	Q13972
VNMEDLREQTHTRHY	SEPTIN6	281	Q14141
RITEYMEHVYLIHRA	OSBPL2	106	Q9H1P3
VPLVAMHHAYVVTER	SARDH	286	Q9UL12
MHHAYVVTERIEGIQ	SARDH	291	Q9UL12
SGVDYCHRHMVVHRD	PRKAA1	136	Q13131
THESHRIYVAIRAMD	CLCA2	856	Q9UQC9
DTLSRVYHMLARSHT	WDR90	686	Q96KV7
RSSDYMRHQRIHTGE	ZNF549	456	Q6P9A3
MRHQRIHTGERAYEC	ZNF549	461	Q6P9A3
IDMAYRVLADHARTI	AARS1	291	P49588
YEVLRTLHHERIMSL	SPEG	3011	Q15772
TLHHERIMSLHEAYI	SPEG	3016	Q15772
MVVSHPHLVAEAYRS	SPOP	341	O43791
NTMDAVPRIDHYRHT	SLC12A2	216	P55011
RLVMLYALHYERHSS	VPS45	386	Q9NRW7
LVELTVHMNETGHYR	TSHZ3	226	Q63HK5
ATHAEHIETIKARMY	TOP3A	536	Q13472
MYNEHLREHAVRFAR	ZNF469	3161	Q96JG9
IVALMRDYLATHVHS	TOR4A	171	Q9NXH8
TFRVAFDVEIHMRTH	ZNF217	136	O75362
HYDRRSMRIEVTCNH	ZNF687	551	Q8N1G0
DSLVHYHMSVELLRS	TRAPPC9	221	Q96Q05
TIRVVSMDRDYHVAC	WTIP	366	A6NIX2
LMEHQRIHTGERLYV	ZNF623	166	O75123
ARTVVEMLLHRHYYL	VRTN	106	Q9H8Y1
SHCYRITYRHMERTL	FARS2	411	O95363
SHYRMFVDVVLVDQH	TBX21	181	Q9UL17
EDMEITSHYRHLLRE	ZBTB46	6	Q86UZ6
LRIHMRTHTEERLYQ	ZNF560	531	Q96MR9